Background
- HCC is associated with significant geriatric comorbidities, with the median age of diagnosis being 65 years.
- Further, multi-kinase inhibitors (MKIs) are associated with up to 60% of grade 3-4 toxicities.
- While not an independent risk factor, age significantly influences patient outcomes.
- We aim to analyze the association of survival with age in HCC and identify molecular markers associated with survival in older patients with HCC receiving TKIs.